Phase II Efficacy Study of Repotrectinib in Frail and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

ROS1 rearrangements are rare, accounting for only 1-2% of NSCLC cases, but have been associated with response to ROS1 inhibitors, such as crizotinib and entrectinib. However, many patients develop resistance to the tyrosine-kinase inhibitors (TKIs), creating a need for new treatments. Repotrectinib is a new-generation TKI designed against ROS1 or NTRK rearranged malignancies (Drilon 2018). Early phase clinical data support activity of repotrectinib in patients with NSCLC harboring such gene rearrangements (TRIDENT-1 study), but there are limited evidence in frail populations, such as poor per

Trial Details

NCT ID
NCT06552234
Phase
PHASE2
Sponsor
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • Repotrectinib
Locations (sample)
  • Aix-en-Provence, Bouches Du Rhône, France|43.5283,5.44973
  • Marseille, Bouches Du Rhône, France|43.29695,5.38107
  • Toulon, Var, France|43.12442,5.92836
  • Angers, France|47.47156,-0.55202
  • Bordeaux, France|44.84124,-0.58046

Key Eligibility Criteria

  • Eligible patients are defined as patients with
  • Eastern Cooperative Oncology Group (ECOG) PS ≥ 2 at the time of inclusion and/or
  • Age ≥ 70 years
  • Age ≥ 18 years

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →